<DOC>
	<DOC>NCT00734565</DOC>
	<brief_summary>This study will investigate safety and reactogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children</brief_summary>
	<brief_title>Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants of either sex, aged 16 20 months / 2 4 months in good health as determined by: medical history physical examination clinical judgment of the investigator; available for all visits scheduled in the study and able to comply with all study regulations; written informed consent obtained, from at least one parent or legal guardian parent or legal guardian is unwilling or unable to give written informed consent to participate in study; infants who presented a previous disease potentially related to Haemophilus influenzae type b; infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease; infants who have received any other Haemophilus influenzae type b immunization dose before (for 1620 months old children who have received a booster vaccination already); premature (before 37th week of gestation) or birth weight less than 2500 g; history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; fever ≥38.0 °C (axillary body temperature) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment; subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease; known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder; subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder; subjects with a clinically significant genetic anomaly; treatment with corticosteroids or other immunosuppressive drugs; treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives (or: within the past 3 months applicable for children 16 20 months); any vaccination administered within 2 weeks (14 days) before enrollment; participation in any other investigational trial simultaneously; planned surgery during the study period; any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>20 Months</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>vaccine</keyword>
	<keyword>prevention</keyword>
	<keyword>haemophilus influenzae type b</keyword>
	<keyword>children</keyword>
</DOC>